Immunotherapy - PD-1 Blocker

Phase 2Small molecule

Immunotherapy - PD-1 Blocker is one of 2 small molecule programs targeting Circadian Rhythm. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Circadian RhythmRecruiting

Circadian RhythmPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Circadian Rhythm

#DrugCompanyPhaseTrials

Spravato

WWim Janssens

Preclinical

1 2

Immunotherapy - PD-1 Blocker

LLiza Villaruz, MD

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2030

Phase 2Recruiting

Circadian Rhythm

NCT07224971

Clinical

Trials by Indication[1]

Circadian Rhythm1 trial

Impact of Circadian Rhythm on Immunotherapy

Recruiting·LLiza Villaruz, MD·Phase 2·NCT07224971·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Immunotherapy - PD-1 Blocker. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunotherapy - PD-1 Blocker compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunotherapy - PD-1 Blocker. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Liza Villaruz, MD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: LLiza Villaruz, MD

Immunotherapy - PD-1 Blocker

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2030

Trials by Indication[1]

Circadian Rhythm1 trial

References

Drug Info

Quick Facts

Related News